{"filing":{"accession_number":"0002007919-26-000047","cik":"0002007919","ticker":"INBX","company_name":"Inhibrx Biosciences, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"inhibrx-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/inhibrx-20260908.htm"},"events":[{"id":31941,"run_id":29337,"accession_number":"0002007919-26-000047","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Inhibrx announced positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% response rate versus 26.5% for the control arm, with particularly strong results in HPV+ patients (80.0% vs 33.3%). The company plans to expand the trial and pursue an accelerated regulatory pathway.","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34981,"accession_number":"0002007919-26-000047","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Inhibrx announced positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% response rate versus 26.5% for the control arm, with particularly strong results in HPV+ patients (80.0% vs 33.3%). The company plans to expand the trial and pursue an accelerated regulatory pathway. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's commercial potential and regulatory trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:04:59.902296+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34982,"accession_number":"0002007919-26-000047","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% confirmed objective response rate versus 26.5% for control, with particularly strong efficacy in HPV+ patients (80.0% cORR). The company plans to expand the Phase 2 study and pursue an accelerated regulatory pathway. While clinical trial results are operationally significant and material to investors assessing the company's pipeline prospects, this does not fit the specific \"earnings_release\" category (which typically refers to financial results) nor any other defined event type. The disclosure is clearly operational/strategic in nature, relating to drug development progress and regulatory strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:04:59.902296+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34981,"accession_number":"0002007919-26-000047","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Inhibrx announced positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% response rate versus 26.5% for the control arm, with particularly strong results in HPV+ patients (80.0% vs 33.3%). The company plans to expand the trial and pursue an accelerated regulatory pathway. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's commercial potential and regulatory trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:04:59.902296+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-09-08"},{"id":34982,"accession_number":"0002007919-26-000047","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% confirmed objective response rate versus 26.5% for control, with particularly strong efficacy in HPV+ patients (80.0% cORR). The company plans to expand the Phase 2 study and pursue an accelerated regulatory pathway. While clinical trial results are operationally significant and material to investors assessing the company's pipeline prospects, this does not fit the specific \"earnings_release\" category (which typically refers to financial results) nor any other defined event type. The disclosure is clearly operational/strategic in nature, relating to drug development progress and regulatory strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:04:59.902296+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-09-08"}]}